Jundishapur Journal of Microbiology

Published by: Kowsar

Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis

Naser Mohammadpour Dounighi 1 , Mehdi Razzaghi-Abyane 2 , Mojtaba Nofeli 1 , Hossein Zolfagharian 1 and Fereshteh Shahcheraghi 3 , *
Authors Information
1 Department of Human Vaccine and Serum, Razi Vaccine and Serum Research Institute, Karaj, IR Iran
2 Department of Mycology, Pasteur Institute of Iran, Tehran, IR Iran
3 Department of Microbiology, Pasteur Institute of Iran, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: July 01, 2016, 9 (7); e34153
  • Published Online: July 9, 2016
  • Article Type: Research Article
  • Received: October 28, 2015
  • Revised: June 21, 2016
  • Accepted: June 28, 2016
  • DOI: 10.5812/jjm.34153

To Cite: Mohammadpour Dounighi N, Razzaghi-Abyane M, Nofeli M, Zolfagharian H, Shahcheraghi F. Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis, Jundishapur J Microbiol. 2016 ; 9(7):e34153. doi: 10.5812/jjm.34153.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Xing D, Markey K, Das RG, Feavers I. Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays. Expert Rev Vaccines. 2014; 13(10): 1175-82[DOI][PubMed]
  • 2. Griffith AH. Permanent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine. 1989; 7(3): 199-210[PubMed]
  • 3. Guiso N. How to fight pertussis? Ther Adv Vaccines. 2013; 1(2): 59-66[DOI][PubMed]
  • 4. Plotkin SA. Pertussis. Vaccine. 1989; 7(3): 195[PubMed]
  • 5. WHO . WHO recommendations for whole-cell pertussis vaccine. 2007;
  • 6. Campbell P, McIntyre P, Quinn H, Hueston L, Gilbert GL, McVernon J. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One. 2012; 7(4): 35874[DOI][PubMed]
  • 7. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California pertussis epidemic, 2010. J Pediatr. 2012; 161(6): 1091-6[DOI][PubMed]
  • 8. van der Maas NA, Mooi FR, de Greeff SC, Berbers GA, Spaendonck MA, de Melker HE. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine. 2013; 31(41): 4541-7[DOI][PubMed]
  • 9. Kmietowicz Z. Pertussis cases rise 10-fold among older children and adults in England and Wales. BMJ. 2012; 345: 5008[DOI][PubMed]
  • 10. Stainer DW, Scholte MJ. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol. 1970; 63(2): 211-20[DOI][PubMed]
  • 11. Guiso N, von Konig CH, Becker C, Hallander H. Fimbrial typing of Bordetello pertussis isolates: agglutination with polyclonal and monoclonal antisera. J Clin Microbiol. 2001; 39(4): 1684-5[PubMed]
  • 12. Gupta RK, Saxena SN, Sharma SB, Ahuja S. Immunogenicity of glutaraldehyde inactivated pertussis vaccine. Vaccine. 1990; 8(6): 563-8[PubMed]
  • 13. Manclark CR, Cowell JL. Pertussis. Bacterial Vaccines. 1984; : 69-106[DOI]
  • 14. Gupta RK, Sharma SB, Ahuja S, Saxena SN. The effects of different inactivating agents on the potency, toxicity and stability of pertussis vaccine. J Biol Stand. 1987; 15(1): 87-98[PubMed]
  • 15. Gupta RK, Sharma SB, Ahuja S, Saxena SN. Glutaraldehyde inactivated pertussis vaccine: a less histamine sensitizing vaccine. J Biol Stand. 1987; 15(2): 159-64[PubMed]
  • 16. Gupta RK, Sharma SB, Ahuja S, Saxena SN. Glutaraldehyde inactivated pertussis vaccine: a safe vaccine in the innocuity test. Vaccine. 1987; 5(2): 102-4[PubMed]
  • 17. Gupta RK, Sharma SB, Ahuja S, Saxena SN. Glutaraldehyde inactivated pertussis vaccine a safe, potent and stable vaccine. Indian J Med Microbiol. 1987; 5: 85-99
  • 18. Iida T, Horiuchi Y. The detoxification of Bordetella pertussis with glutaraldehyde. J Biol Stand. 1987; 15(1): 17-26[PubMed]
  • 19. Gupta RK, Saxena SN, Sharma SB, Ahuja S. Studies on the optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for preparation of a safe and potent pertussis vaccine. Vaccine. 1988; 6(6): 491-6[PubMed]
  • 20. WHO . WHO expert committee on biological standardization. 1990;
  • 21. WHO . WHO expert committee on biological standardization: fifty-sixth report. 2007;
  • 22. WHO . WHO Technical Report Series. 1976;
  • 23. Prasath CS, Siva MN, Regin BS, Prakash S. Lab scale production of pertussis vaccine in b2 medium with the different concentration of bactocasamino acid, yeast extract and soluble starch. Int J Biotech Biochem. 2010; 6: 147-56
  • 24. WHO . Testing for whole cell pertussis vaccine. WHO Manual for Quality Control of Diphtheria, Tetanus and Pertussis Vaccines. . 2013; : 213
  • 25. British Pharmacopoia. 2014;
  • 26. van Ramshorst JD. Toxicity control of pertussis vaccines by the mouse weight gain test. Prog Immunobiol Stand. 1967; 3: 324-6[PubMed]
  • 27. Gupta RK, Sharma SB, Ahuja S, Saxena SN. Evaluation of repeated immunoassays (mouse intracerebral potency tests) of the second International Standard of Pertussis Vaccine. J Immunoassay. 1987; 8(4): 309-18[PubMed]
  • 28. Ahuja S, Gupta RK, Sharma SB, Saxena SN. Loss in the opacity of bacterial organisms during their inactivation for the production of whole cell vaccines. Ind J Med Microbiol. 1987; 5: 43-51
  • 29. Preston NW. Essential immunogens in human pertussis: the role of fimbriae. Dev Biol Stand. 1985; 61: 137-41[PubMed]
  • 30. Preston NW. Protection by pertussis vaccine. Little cause for concern. Lancet. 1976; 1(7968): 1065-7[PubMed]
  • 31. Cameron J, Desormeaux Y, De Bellefeuille ML, Leclerc J. Toxicity testing of pertussis vaccines: effect of increased sensitivity of mice to Bordetella pertussis. J Biol Stand. 1984; 12(1): 19-24[PubMed]
  • 32. Xing D, Das RG, O'Neill T, Corbel M, Dellepiane N, Milstien J. Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test. Vaccine. 2001; 20(3-4): 342-51[PubMed]
  • 33. Das RG, Newland P, Asokanathan C, Douglas-Bardsley A, Corbel M, Xing D. Evaluation of fourth international standard for whole cell pertussis vaccine. Biologicals. 2010; 38(6): 644-51[DOI][PubMed]
  • 34. Cherry JD. Pertussis: challenges today and for the future. PLoS Pathog. 2013; 9(7): 1003418[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments